Pyxis Oncology, Inc. (PYXS) Ownership
PYXS ownership summary
as of October 18, 2026- Institutions
- 39.6% of shares outstanding
- Insiders
- 9.47% of shares outstanding
- Shares outstanding
- 119.5M
- Float
- 54.7M shares available to trade
- Short interest
- 7.31% 4.9M shares short
- Days to cover
- 3.95 short interest up 4.4% vs prior month
- Institutions 39.56%
- Insiders 9.47%
- Other investors 50.97%
PYXS top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 15.99% | 10.0M | $16.8M | +5.9M (+143.2%) | June 30, 2026 |
| 2 | Pfizer Inc | 11.22% | 7.0M | $11.8M | — | June 30, 2026 |
| 3 | LAURION CAPITAL MANAGEMENT LP | 7.82% | 4.9M | $8.2M | −96,445 (−1.9%) | June 30, 2026 |
| 4 | Vanguard Capital Management, LLC | 3.31% | 2.1M | $3.5M | +42,487 (+2.1%) | June 30, 2026 |
| 5 | Atle Fund Management AB | 1.54% | 966K | $1.6M | +769,423 (+390.5%) | June 30, 2026 |
| 6 | 683 Capital Management LLC | 1.43% | 896K | $1.5M | +4,353 (+0.5%) | March 31, 2026 |
| 7 | BlackRock Inc | 1.38% | 868K | $1.5M | +79,095 (+10.0%) | June 30, 2026 |
| 8 | Palo Alto Investors, LLC | 1.38% | 864K | $1.5M | −146,233 (−14.5%) | June 30, 2026 |
| 9 | Marshall Wace Asset Management Ltd | 1.32% | 831K | $1.4M | +476,127 (+134.3%) | June 30, 2026 |
| 10 | Renaissance Technologies Corp | 1.23% | 772K | $1.3M | −116,448 (−13.1%) | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 0.94% | 592K | $994,306 | −6,272 (−1.0%) | June 30, 2026 |
| 12 | Woodline Partners LP | 0.84% | 524K | $880,318 | +523,999 (0.0%) | June 30, 2026 |
| 13 | Jacobs Levy Equity Management, Inc. | 0.68% | 429K | $720,058 | −32,391 (−7.0%) | June 30, 2026 |
| 14 | Longaeva Partners L.P. | 0.56% | 354K | $594,018 | −149,632 (−29.7%) | June 30, 2026 |
| 15 | Decheng Capital LLC | 0.52% | 327K | $549,041 | — | June 30, 2026 |
| 16 | Vanguard Fiduciary Trust Co | 0.48% | 303K | $509,016 | +2,089 (+0.7%) | June 30, 2026 |
| 17 | Jane Street Group LLC | 0.46% | 290K | $487,351 | −14,369 (−4.7%) | June 30, 2026 |
| 18 | State Street Corp | 0.40% | 249K | $418,046 | — | June 30, 2026 |
| 19 | Millennium Management LLC | 0.37% | 233K | $391,447 | −164,621 (−41.4%) | June 30, 2026 |
| 20 | UBS Group AG | 0.25% | 155K | $260,765 | −98,907 (−38.9%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 8 holders added 7.8M shares and 9 cut 825K.
PYXS top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.57% | 1.6M | $2.7M | — | August 31, 2026 |
| 2 | iShares Biotechnology ETF | 0.85% | 532K | $894,459 | −4,032 (−0.8%) | September 30, 2026 |
| 3 | HealthInvest Sustainable Healthcare E | 0.76% | 474K | $795,876 | −17,283 (−3.5%) | September 30, 2026 |
| 4 | Fidelity Extended Market Index | 0.41% | 258K | $434,115 | −1,389 (−0.5%) | August 31, 2026 |
| 5 | HealthInvest S&M Cap Healthcare C | 0.30% | 190K | $319,519 | −182,407 (−49.0%) | September 30, 2026 |
| 6 | iShares Micro-Cap ETF | 0.25% | 155K | $260,111 | −1,068 (−0.7%) | September 30, 2026 |
| 7 | Fidelity Nasdaq Composite Index | 0.20% | 123K | $206,232 | +82,867 (+207.7%) | August 31, 2026 |
| 8 | Fidelity Total Market Index | 0.15% | 96K | $161,784 | +6,095 (+6.8%) | August 31, 2026 |
| 9 | EA Bridgeway Ultra-Small Company Mkt ETF | 0.15% | 94K | $158,162 | — | September 30, 2026 |
| 10 | Fidelity Series Total Market Index | 0.13% | 82K | $137,802 | +3,316 (+4.2%) | August 31, 2026 |
| 11 | iShares Nasdaq US Biotech ETF USD Acc | 0.11% | 69K | $115,154 | +596 (+0.9%) | September 30, 2026 |
| 12 | BSF Systematic US Eq Abs Ret A2 USD | 0.10% | 62K | $104,353 | — | December 31, 2025 |
| 13 | Mackenzie GQE US Small Cap F8 | 0.04% | 27K | $46,067 | +18,837 (+219.4%) | July 31, 2026 |
| 14 | Vanguard Balanced Index Inv | 0.04% | 27K | $45,135 | — | August 31, 2026 |
| 15 | Vanguard MStar Inst Ttl StkMktIdxInstlPl | 0.04% | 27K | $44,772 | — | August 31, 2026 |
| 16 | Vanguard U.S. Eq Idx £ Acc | 0.03% | 21K | $35,687 | — | August 31, 2026 |
| 17 | 1290 VT Micro Cap K | 0.02% | 11K | $18,796 | — | August 31, 2026 |
| 18 | DFA US Micro Cap I | 0.02% | 10K | $17,242 | — | August 31, 2026 |
| 19 | China Universal NASDAQ Bio-Tch ETF(QDII) | 0.02% | 10K | $16,939 | −63 (−0.6%) | June 30, 2026 |
| 20 | Dimensional World Equity GBP Acc | 0.01% | 6,396 | $10,745 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
PYXS insider transactions
latest 13| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-21 | Rachel Humphrey | Sell | $1.03 | 13,896 | $14,313 |
| 2025-04-17 | Rachel Humphrey | Sell | $0.97 | 200 | $194 |
| 2025-04-14 | Rachel Humphrey | Sell | $0.97 | 1,400 | $1,358 |
| 2024-11-26 | Pamela Ann Connealy | Buy | $1.96 | 88,850 | $174,146 |
| 2023-09-27 | Jitendra Wadhane | Buy | $1.87 | 2,500 | $4,675 |
| 2023-09-27 | Pamela Ann Connealy | Buy | $1.85 | 6,426 | $11,888 |
| 2023-09-25 | Jitendra Wadhane | Buy | $1.77 | 5,000 | $8,850 |
| 2023-09-25 | Pamela Ann Connealy | Buy | $1.67 | 12,000 | $20,040 |
| 2023-09-22 | Jitendra Wadhane | Buy | $1.74 | 2,500 | $4,350 |
| 2023-09-22 | Pamela Ann Connealy | Buy | $1.74 | 5,000 | $8,700 |
| 2023-09-18 | Lara Sullivan | Sell | $2.10 | 8,541 | $17,936 |
| 2023-09-13 | Lara Sullivan | Sell | $2.27 | 3,000 | $6,810 |
| 2023-09-11 | Lara Sullivan | Sell | $2.27 | 20,000 | $45,400 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
PYXS shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns PYXS
Institutional investors own 39.6% of Pyxis Oncology's shares and insiders 9.47%. The largest holder is GordonMD Global Investments LP with 15.99% of the shares (10.0M), as of June 30, 2026. Among the top 20 institutions, 8 added shares and 9 reduced their stake in the latest filings. Short interest is 7.31% of the float, or 3.95 days of average trading volume. The share count rose 180.9% since 2020.
Related: PYXS analyst forecast, PYXS key metrics. See the PYXS stock overview for the latest quote and news.
PYXS ownership FAQ
Who owns the most Pyxis Oncology stock?
The largest shareholders of Pyxis Oncology are GordonMD Global Investments LP (15.99%), Pfizer Inc (11.22%), LAURION CAPITAL MANAGEMENT LP (7.82%), Vanguard Capital Management, LLC (3.31%), Atle Fund Management AB (1.54%).
What percentage of Pyxis Oncology is owned by institutions?
Institutions hold 39.6% of Pyxis Oncology's shares outstanding; insiders hold 9.47%.
Which funds own Pyxis Oncology?
The largest fund holders of Pyxis Oncology are Vanguard MStar Total Stk Mkt Idx Invest (2.57%), iShares Biotechnology ETF (0.85%), HealthInvest Sustainable Healthcare E (0.76%), Fidelity Extended Market Index (0.41%), HealthInvest S&M Cap Healthcare C (0.30%).
What is Pyxis Oncology's short interest?
4.9M shares of Pyxis Oncology were sold short, 7.31% of the float; at the average daily volume it would take 3.95 days to cover.
Are insiders buying or selling Pyxis Oncology?
Of the latest 13 reported insider transactions in Pyxis Oncology (since September 11, 2023), 7 were purchases and 6 were sales.
How many shares of Pyxis Oncology are outstanding?
Pyxis Oncology has 119.5M shares outstanding, of which 54.7M are in the public float.